|
Year to Mar 2024
12 months to Mar 31, 2024
|
Year to Mar 2023
12 months to Mar 31, 2023
|
Year to Mar 2022
12 months to Mar 31, 2022
|
Year to Mar 2021
12 months to Mar 31, 2021
|
|
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net loss for the year | ||||
| Adjustments for non-cash items: | ||||
| Share-based compensation expense | ||||
| Change in fair value of warrant liability | ||||
| Change in fair value of deferred purchase price payable - Tarus and deferred obligation - iOx milestone | ||||
| Loss on Registered Direct Offering | ||||
| Offering costs | ||||
| Impairment loss | ||||
| iOx IPR&D | ||||
| Tarus IPR&D | ||||
| Stimunity | ||||
| Saugatuck | ||||
| Goodwill [member] | ||||
| Change in fair value of deferred purchase price payable – Tarus and deferred obligation – iOx milestone | ||||
| Commitment fee under Committed Purchase Agreement | ||||
| Gain on dissolution of investment in associate | ||||
| Gain from sale of investment in public company | ||||
| Decrease in deferred tax liability | ||||
| Share of loss in associate | ||||
| Fair value of shares issued for services | ||||
| Depreciation | ||||
| Foreign exchange transaction gain | ||||
| Changes in operating working capital: | ||||
| Accounts receivable | ||||
| Prepaid expenses and other receivables | ||||
| Other assets | ||||
| Accounts payable and accrued liabilities | ||||
| Other | ||||
| Net cash used in operating activities | ||||
| Cash flows from investing activities: | ||||
| Proceeds from sale of investment in public company | ||||
| Purchase of convertible note receivable | ||||
| Purchase of equipment | ||||
| Net cash provided by (used in) investing activities | ||||
| Cash flows from financing activities: | ||||
| Proceeds from Registered Direct Offering | ||||
| Proceeds from shares issued under ATM and Committed Purchase Agreement | ||||
| Share issuance costs | ||||
| Repayment of lease liability | ||||
| Shares from RSU distribution | ||||
| Repayment of notes payable assumed in Tarus acquisition | ||||
| Repayment of milestone obligation assumed in Tarus acquisition | ||||
| Proceeds from shares issued under registered offering | ||||
| Proceeds from exercise of stock purchase warrants | ||||
| Net cash provided by (used in) financing activities | ||||
| Decrease in cash and cash equivalents during year | ||||
| Cash and cash equivalents at beginning of year | ||||
| Cash and cash equivalents at end of year | ||||
| Supplemental disclosure of cash flow information: | ||||
| Cash paid for interest | ||||
| Increase in accounts payable for stock issuance costs | ||||
| Supplemental disclosure of non-cash investing and financing activities: | ||||
| Decrease in warrant liability from warrant exercise | ||||
| Exchange of Stimunity Convertible Note for Stimunity shares at fair value | ||||
| Right to use asset acquired | ||||
| Lease liability incurred | ||||
| Fair value of shares issued for Tarus | ||||
| Fair value of shares issued for non-controlling interest purchase of iOx | ||||
| Fair value of deferred purchase price payable - Tarus | ||||
| Fair value of deferred obligation - iOx milestone | ||||
| Liabilities assumed in Tarus acquisition | ||||
| Fair value of shares issued for commitment fees - Committed Purchase | ||||
| Net unrealized loss on investments in Intensity and Stimunity Convertible Note | ||||
| Exchange of iOx shares for settlement of notes payable, accrued interest and warrants | ||||
Loading...
